Compare DVAX & PZZA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DVAX | PZZA |
|---|---|---|
| Founded | 1996 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.2B |
| IPO Year | 2004 | 1993 |
| Metric | DVAX | PZZA |
|---|---|---|
| Price | $15.63 | $36.14 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 9 |
| Target Price | $26.50 | ★ $47.44 |
| AVG Volume (30 Days) | ★ 5.6M | 815.9K |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 5.09% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.14 |
| Revenue | $330,514,000.00 | ★ $2,086,399,000.00 |
| Revenue This Year | $24.63 | $2.60 |
| Revenue Next Year | $15.85 | N/A |
| P/E Ratio | ★ N/A | $31.78 |
| Revenue Growth | ★ 26.73 | N/A |
| 52 Week Low | $9.20 | $30.16 |
| 52 Week High | $15.73 | $55.74 |
| Indicator | DVAX | PZZA |
|---|---|---|
| Relative Strength Index (RSI) | 85.75 | 32.18 |
| Support Level | $15.57 | $36.79 |
| Resistance Level | $15.73 | $38.48 |
| Average True Range (ATR) | 0.06 | 1.33 |
| MACD | -0.05 | -0.10 |
| Stochastic Oscillator | 70.83 | 4.26 |
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Papa John's is one of the largest players in the global QSR, or quick-service restaurant, pizza market, boasting more than 6,000 restaurants across nearly 50 countries at the end of 2024. The firm operates a predominantly franchised system, owning 9% of its restaurants and generating revenue from franchise royalties, sales of pizza and related products at its company-owned stores, and sales from its commissary supply chain. The firm is the fourth-largest limited-service pizza chain globally and third in the US (Euromonitor International), with a sizable presence in the UK, China, South Korea, and Chile.